Reviewed, never approved
Is Ipamorelin FDA-Approved? Regulatory Status
The short answer is no. The longer answer — a failed trial, a 2024 compounding-list removal, and a permanent research-chemical status — is the interesting part.
The blunt version
Is ipamorelin FDA approved? No — not for any indication, not anywhere. Here's the plain story. Ipamorelin was developed in the 1990s and tested in humans, but the only proper trial (for slow bowel recovery after surgery) failed [3]. No company ever brought it across the approval line, so it has no approved medical use and no FDA-cleared label. For years it lived in a gray zone where compounding pharmacies could sometimes prepare it — until 2024, when the FDA tightened that too. Today it is sold strictly as a "research chemical," which is a category, not an endorsement: it means no regulator has vouched for its safety, quality, or effectiveness. If a clinic or seller implies otherwise, the regulatory record says they're overstating it.
What 'never approved' actually means here
Ipamorelin has never been approved as a drug by the FDA, the EMA, or any other regulatory authority [3]. That's not a paperwork lag — it reflects that the development programs didn't deliver. The single published Phase 2 RCT (NCT00672074, 114 patients) for postoperative ileus missed its primary endpoint, with a time-to-tolerated-meal difference that didn't reach significance (25.3 h vs 32.6 h, p=0.15) [3]. No Phase 3 trial followed, and no other indication advanced that far. So the absence of approval is the absence of demonstrated efficacy, not merely an incomplete filing. "Investigational" is the accurate word; "approved" is not.
The 2024 compounding crackdown
The most recent regulatory move sharpened the picture. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list — the framework that governs which raw substances compounding pharmacies may use — following the nominator's withdrawal in September 2024. The agency reviewed ipamorelin acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting. The upshot: ipamorelin is not an approved bulk substance for compounding, which narrows the already-thin legitimate access route. 503A and PCAC are the FDA's pharmacy-compounding machinery; the 2024 action moved ipamorelin further out of bounds, not further in.
Approved-adjacent confusion to avoid
A frequent mix-up: because ipamorelin is often paired with GHRH analogs, people assume it inherits their status. It doesn't. Tesamorelin (a GHRH analog) has a real approved human indication; sermorelin had an approved-drug history. Ipamorelin is neither — it's a ghrelin-receptor agonist [1] that cleared no regulatory bar of its own. The CJC-1295 + ipamorelin combination is likewise unapproved and untested as a combination [3]. None of the stack's components lend ipamorelin an approval it never earned. When evaluating any claim, the relevant fact is ipamorelin's own record: investigated, failed its one efficacy trial, never approved.
What its status is now
Ipamorelin is marketed only as a research chemical, explicitly not approved for human consumption or therapeutic use [3]. On top of the FDA picture, it is prohibited in sport under WADA category S2 and detectable in urine by accredited labs [7]. Two 2026 reviews classify it as an investigational GH-axis peptide with an uncertain safety profile, variable product quality, and no reproducible human efficacy for the outcomes it's marketed for [11][13]. The bottom line a reader should leave with: not FDA-approved, access tightened in 2024, banned in sport, and supported by a human evidence base that is thin and, where it exists, negative.